GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Fosun Pharmaceutical (Group) Co Ltd (OTCPK:SFOSF) » Definitions » Ending Cash Position

Shanghai Fosun Pharmaceutical (Group) Co (Shanghai Fosun Pharmaceutical (Group) Co) Ending Cash Position : $1,298 Mil (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Shanghai Fosun Pharmaceutical (Group) Co Ending Cash Position?

Shanghai Fosun Pharmaceutical (Group) Co's Ending Cash Position for the quarter that ended in Mar. 2024 was $1,298 Mil.

Shanghai Fosun Pharmaceutical (Group) Co's quarterly Ending Cash Position declined from Sep. 2023 ($1,382 Mil) to Dec. 2023 ($1,331 Mil) and declined from Dec. 2023 ($1,331 Mil) to Mar. 2024 ($1,298 Mil).

Shanghai Fosun Pharmaceutical (Group) Co's annual Ending Cash Position increased from Dec. 2021 ($1,014 Mil) to Dec. 2022 ($1,602 Mil) but then declined from Dec. 2022 ($1,602 Mil) to Dec. 2023 ($1,331 Mil).


Shanghai Fosun Pharmaceutical (Group) Co Ending Cash Position Historical Data

The historical data trend for Shanghai Fosun Pharmaceutical (Group) Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Fosun Pharmaceutical (Group) Co Ending Cash Position Chart

Shanghai Fosun Pharmaceutical (Group) Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,181.17 1,120.13 1,014.20 1,602.20 1,330.83

Shanghai Fosun Pharmaceutical (Group) Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,758.95 1,683.94 1,381.52 1,330.83 1,298.43

Shanghai Fosun Pharmaceutical (Group) Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Shanghai Fosun Pharmaceutical (Group) Co's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=1564.393+-233.563
=1,331

Shanghai Fosun Pharmaceutical (Group) Co's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=1319.5+-21.07
=1,298


Shanghai Fosun Pharmaceutical (Group) Co Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Shanghai Fosun Pharmaceutical (Group) Co's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Fosun Pharmaceutical (Group) Co (Shanghai Fosun Pharmaceutical (Group) Co) Business Description

Address
No. 1289 Yishan Road, Building A, Fosun Technology Park, Shanghai, CHN, 200233
Shanghai Fosun Pharmaceutical (Group) Co Ltd is a specialty and generic drug manufacturing company. Shanghai Fosun maintains five business segments, including Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. Most of the company's revenue is generated by its Pharmaceutical manufacturing segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Shanghai Fosun Pharmaceutical (Group) Co (Shanghai Fosun Pharmaceutical (Group) Co) Headlines

From GuruFocus

Fosun Pharma Announces 2022 Interim Results

By PRNewswire PRNewswire 08-30-2022

Fosun Pharma Announces 2021 Interim Results

By PRNewswire PRNewswire 08-24-2021